Catalyst Pharmaceutical Partners’ (CPRX) “Buy” Rating Reaffirmed at Roth Capital
Roth Capital reaffirmed their buy rating on shares of Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) in a report issued on Friday. The firm currently has a $2.50 price objective on the biopharmaceutical company’s stock.
Several other equities research analysts have also recently weighed in on CPRX. Zacks Investment Research cut Catalyst Pharmaceutical Partners from a buy rating to a hold rating in a report on Tuesday, July 12th. Piper Jaffray Cos. upgraded Catalyst Pharmaceutical Partners from a neutral rating to an overweight rating and set a $4.00 price objective for the company in a report on Wednesday, October 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $3.38.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded up 2.22% during midday trading on Friday, reaching $1.38. The company had a trading volume of 215,642 shares. Catalyst Pharmaceutical Partners has a one year low of $0.51 and a one year high of $3.55. The company’s market capitalization is $114.36 million. The company has a 50-day moving average price of $1.13 and a 200 day moving average price of $0.89.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. Equities analysts anticipate that Catalyst Pharmaceutical Partners will post ($0.25) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada bought a new position in Catalyst Pharmaceutical Partners during the second quarter worth $117,000. Point72 Asset Management L.P. raised its position in Catalyst Pharmaceutical Partners by 4.6% in the second quarter. Point72 Asset Management L.P. now owns 2,366,964 shares of the biopharmaceutical company’s stock worth $1,681,000 after buying an additional 103,388 shares during the period. Paloma Partners Management Co bought a new position in Catalyst Pharmaceutical Partners during the second quarter worth $200,000. DRW Securities LLC bought a new position in Catalyst Pharmaceutical Partners during the second quarter worth $168,000. Finally, Oxford Asset Management raised its position in Catalyst Pharmaceutical Partners by 3.5% in the second quarter. Oxford Asset Management now owns 180,721 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 6,140 shares during the period. 30.64% of the stock is owned by institutional investors.
Catalyst Pharmaceutical Partners Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Stock Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related stocks with our FREE daily email newsletter.